•
Shenzhen-based vascular intervention specialist OrbusNeich Medical Group Ltd (HKG: 6929) has announced a significant distribution agreement with Cardiovascular Systems Inc. (CSI), a subsidiary of U.S. giant Abbott Laboratories (NYSE: ABT). Under this agreement, CSI will serve as the exclusive distributor of OrbusNeich’s coronary and peripheral balloon products in the United…
•
OrbusNeich Medical Group Ltd (HKG: 6929), a Wholly Owned Foreign Enterprise (WOFE) specializing in vascular intervention based in Shenzhen, is poised to acquire an 84% stake in Indonesia-headquartered PT Revass Utama Medika for a consideration between USD 10.08 million to USD 20.16 million. PT Revass Utama Medika, which is focused…